Purchase this article with an account.
Julia Malalis, Christine Mata, Daniel Kahn, Amy Lin, Michael Mosier, Charles Bouchard, Josephine Cunanan, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed; Proteomic Analysis of Plasma and Mucosal Samples from Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2062. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are life-threatening, immune-complex hypersensitivity reactions that affect the skin and mucous membranes, often resulting in significant ocular inflammation. The purpose of this study was to determine and compare the proteomic and coagulation profile of plasma and mucosal discharge samples in affected and unaffected patients.
Following institutional review board approval, plasma and swabs from ocular, oral, and skin lesions were obtained from patients with clinically suspected SJS/TEN (n=5). Two patients had biopsy-proven SJS/TEN. Three patients had alternative skin diagnoses not consistent with SJS/TEN and were considered abnormal controls. Samples from normal healthy controls were also obtained. Following centrifugation, the plasma was frozen at -70°C and later thawed and analyzed to determine thrombin-antithrombin complex (TAT, Dade®, Marburg, Germany), fibrinopeptide (F1.2, Dade®), plasminogen activator inhibitor-1 (PAI-1, Diagnostica Stago®, Asnieres Sur Seine, France), ZYMUPHEN platelet microparticle activity (Hyphen® BioMed, Neuville-Sur Oise, France), HEMOCLOT protein C (Stago®), and STACHROME antithrombin (Stago®), using ELISA kits as per manufacturer’s instructions. The swabs were immediately frozen at -70°C and later thawed. The discharges were isolated following addition of 0.25 ml of saline to each swab and double centrifugation. The discharges and plasma samples were analyzed using SELDI-TOF technique.
Analyses of the SJS/TEN plasma samples revealed a marked increase in the TAT complexes (6.3±5.9µg/ml), F1.2 (430.4±202.4 pmol/L), platelet microparticles (13.1±9.3nM) and protein C levels (90.5±63.4%), with a corresponding decrease in PAI-1 (53.3±18.8ng/ml) and antithrombin levels (80.7±42.4%) compared to normal control human plasma, suggesting a procoagulant state. Protein chip array of the SJS/TEN skin and oral mucosal samples exhibited two major peaks at 14.2 kDa and 15.6 kDa, in the same molecular weight range as recombinant human granulysin, a molecule implicated in the pathophysiology of SJS/TEN. These peaks were not present in the control group.
Procoagulant factors and unique peaks suggestive of granulysin may lead to the development of targeted therapy aimed to attenuate local and systemic inflammatory processes in patients with SJS/TEN.
This PDF is available to Subscribers Only